Lifeward's Strategic Pivot: From MedTech to a Diversified Biomedical Platform
With the Oratech acquisition and a strengthened balance sheet, Lifeward is betting on a biotech option while stabilizing its core neurorehabilitation business.
LFWD · Earnings Call · 2026-05-15
What Changed?
Lifeward's first-quarter 2026 report was a tale of two stories: a transformative strategic pivot and an operational reset. The completion of the AlterG shipment issues aside, the headline was the acquisition of Oratech, which CEO Mark Grant described as a move to become a "diversified biomedical innovation company." This equity-based deal brought a protein oral delivery platform, including ORMD-0801 oral insulin, without significant near-term operational burden. As Grant explained,
We believe this transaction significantly strengthens Lifeward's position as a diversified biomedical innovation company while reinforcing our focus on neurorehabilitation and our path toward profitability.
The company also added an upper body exoskeleton for stroke survivors, further complementing its ReWalk platform. These moves signal a deliberate shift toward aggregating innovative technologies with low execution risk, leveraging Grant's three decades of commercial experience in metabolic disease and channel development.
Financial Discipline Meets Balance Sheet Strength
Fundamentally, Lifeward used the quarter to shore up its liquidity. The company closed a $10 million convertible note financing and ended the quarter with $11.4 million in unrestricted cash, compared to just $2.2 million at year-end 2025. Effective net cash improved to $15 million, a 10% increase YoY. CFO Almog Adar highlighted a 33% reduction in cash used in operations, driven by improved working capital management and efficiency gains. Adjusted operating expenses fell 12% to $5.9 million, reflecting a leaner cost structure. However, total revenue dipped to $4 million, down 22% YoY, as “temporary timing disruptions associated with working capital constraints late last year” — William Grant, President and Chief Executive Officer · 2026-05-15 hit AlterG shipments. Gross margin contracted to 34.2% from 42.2%, with FX and tariffs responsible for 75–85% of the decline, per Adar. Gross margin at 34.2% reflects lower absorption and higher freight costs, though management expects improvement as volumes recover.
Commercial Progress: ReWalk Up, AlterG Catching Up
Despite the revenue drag, ReWalk personal exoskeleton sales grew 11% YoY to $1.6 million, driven by international growth and expanding reimbursement coverage, including deals with Aetna, Humana, and UnitedHealthcare. Grant noted, “I would expect that we have similar to last year. And I would also expect the exit trajectory to be better than it is the entry trajectory.” — William Grant, President and Chief Executive Officer · 2026-05-15 The company has a backlog of AlterG orders and expects to ship through Q2 and Q3. This is a recurring theme from earlier calls: in the Q4 2025 call, Almog Adar had said, “Q4 is usually the strongest quarter for us at ReWalk for both products, AlterG and ReWalk, and what gives me the confidence that we will achieve our guidance is the existing backlog for both products and the strong pipeline that we are managing.” — Almog Adar, Chief Financial Officer · 2025-11-14 The strategic shift toward channel partners and manufacturing transition is still unfolding, but the company is positioning itself as an executor that can exploit payers and distribution networks.
Outlook and Risks
Management reiterated that full-year revenue should be similar to last year, with an improving trajectory exiting 2026. The biomedical platform provides a potential high-value option via oral insulin, with minimal cash burn. That said, the company remains heavily dependent on AlterG recovery and sustained ReWalk momentum. The stock has surged 11% over the last 90 days, but it remains deeply below historical highs. The key risk is whether the operational stabilization translates into consistent growth and a path to profitability, especially as the company balances multiple initiatives.